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Background
Tumor necrosis factor (TNF) antagonist therapies chan-
ged the rheumatoid arthritis treatment paradigm but
arguments to choose among anti-TNF are lacking.
The aim of this work was to evaluate the comparative
effectiveness of adalimumab, etanercept and infliximab
over 1 year in clinical practice.
Secondary aims were to look for clinical predictors of
response.
Methods
Analyses were performed upon Reuma.pt. Response to
therapy was defined according to EULAR criteria. Prob-
ability of response was modeled. Multivariate logistic
regression model predicting response over 1 year with
all variables and automated stepwise selection models
were built. In addition, we performed analyses using
propensity score 1:1:1 nearest neighbor matching algo-
rithms to obtain comparable groups regarding baseline
features.
Results
632 RA patients, 250 treated with etanercept, 206 with
infliximab and 161 with adalimumab were evaluated.
At baseline visit, infliximab treated patients were sig-
nificantly older, had lower education level, more comor-
bidities and more concomitant therapies.
We have found significant negative association with
anti-TNF response and smoking, presence of RF and
ACPA and higher physician VAS at baseline.
In unadjusted analysis, proportion of good response
over 1 year was 59.2% in etanercept, 52% in infliximab
and 59.6% in adalimumab group (p=0.21). GLM showed
no significant differences between the 3. Multivariate
logistic regression analyses demonstrated similar effec-
tiveness. Also, no significant differences in treatment
response were detected after applying the matching pro-
pensity score analysis.
Conclusion
Smoking, RF, ACPA and physician VAS were identified
as predictors of response. In our study using different
statistic techniques, we observed similar efficacy over 1
year for the 3 anti-TNF agents studied.
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